Gitte Aabo - GN Store Chief Hearing
| GNNDY Stock | USD 52.66 0.64 1.20% |
Executive
Ms. Gitte Pugholm Aabo was Independent Director at GN STORE NORD AS since March 13, 2018. She holds MBA, HD graduate diploma in business administration, Bachelor of economy. She is CEO, LEO Pharma AS. She also serves as Member of the Committee of Directors of Danmarks Nationalbank, the American Skin Association Board, the American Skin Association Education Council, the European Federation of Pharmaceutical Industries and Associations. She has leadership experience from the pharma industry and special knowledge within international management, finance previously as CFO of LEO Pharma IT, sales and marketing in the medical sector as well as deep insights into building digital communities. since 2018.
| Age | 56 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Phone | 45 45 75 00 00 |
| Web | https://www.gn.com |
GN Store Management Efficiency
The company has return on total asset (ROA) of 0.0376 % which means that it generated a profit of $0.0376 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0875 %, meaning that it generated $0.0875 on every $100 dollars invested by stockholders. GN Store's management efficiency ratios could be used to measure how well GN Store manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Michele Allegretto | Glaukos Corp | N/A | |
| Tracy Founds | Glaukos Corp | N/A | |
| Deina Walsh | Bone Biologics Corp | 60 | |
| Jan Metzdorff | Sonova Holding AG | 60 | |
| Deina CPA | Bone Biologics Corp | 61 | |
| Andres Cedron | Orthofix Medical | 44 | |
| Mohan Sancheti | Procept Biorobotics Corp | 61 | |
| David Hackshall | CochLear Ltd ADR | N/A | |
| Brent JD | Bruker | 49 | |
| Barry Templin | Procept Biorobotics Corp | N/A | |
| Darleen Caron | Siemens Healthineers AG | 59 | |
| Jane Rady | Glaukos Corp | 76 | |
| Jill Mason | Orthofix Medical | N/A | |
| Stephanie Walsh | Orthofix Medical | N/A | |
| Julie Dewey | Orthofix Medical | 64 | |
| Thomas Bures | Bruker | 50 | |
| Dan Yarbrough | Orthofix Medical | N/A | |
| Lucas Vitale | Orthofix Medical | 47 | |
| Christopher Lewis | Glaukos Corp | N/A | |
| Niels Wagner | Demant AS ADR | 52 | |
| Matthew CFA | Procept Biorobotics Corp | N/A | |
Management Performance
| Return On Equity | 0.0875 | |||
| Return On Asset | 0.0376 |
GN Store Nord Leadership Team
Elected by the shareholders, the GN Store's board of directors comprises two types of representatives: GN Store inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GNNDY. The board's role is to monitor GN Store's management team and ensure that shareholders' interests are well served. GN Store's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GN Store's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anne Veyhe, Treasury Relations | ||
| Peter Gormsen, Chief Officer | ||
| Rene SvendsenTune, Member of the Executive Management Team, CEO of GN Netcom | ||
| Steen Laursen, VP Communication | ||
| Gitte Aabo, Chief Hearing | ||
| Gunther Pausch, Head RD | ||
| Aurangzeb Khan, VP Jabra | ||
| Ehtisham Rabbani, CEO SteelSeries | ||
| Lars AndersenLange, Head Affairs | ||
| Brian Pedersen, Chief Officer |
GNNDY Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is GN Store a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0875 | |||
| Return On Asset | 0.0376 | |||
| Profit Margin | 0.03 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 5.06 B | |||
| Shares Outstanding | 42.66 M | |||
| Price To Earning | 14.99 X | |||
| Price To Book | 2.86 X | |||
| Price To Sales | 0.17 X | |||
| Revenue | 18.69 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for GNNDY Pink Sheet Analysis
When running GN Store's price analysis, check to measure GN Store's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GN Store is operating at the current time. Most of GN Store's value examination focuses on studying past and present price action to predict the probability of GN Store's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GN Store's price. Additionally, you may evaluate how the addition of GN Store to your portfolios can decrease your overall portfolio volatility.